CONCORDBIO - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | CONCORDBIO | Market Cap | 11,938 Cr. | Current Price | 1,141 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 37.6 | Book Value | 174 ₹ | Dividend Yield | 0.94 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,222 ₹ | DMA 200 | 1,443 ₹ |
| Chg in FII Hold | -0.45 % | Chg in DII Hold | 0.03 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 43.4 | MACD | -16.3 | Volume | 4,23,536 | Avg Vol 1Wk | 2,61,497 |
| Low price | 1,057 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.40 | Debt to equity | 0.00 |
| 52w Index | 7.74 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 27.6 |
📊 Chart & Trend Analysis: CONCORDBIO is trading at ₹1,141, below both its 50 DMA (₹1,222) and 200 DMA (₹1,443), signaling weakness and bearish undertone. RSI at 43.4 indicates the stock is nearing oversold territory but not yet at reversal strength. MACD at -16.3 confirms bearish momentum. Bollinger Bands show price leaning towards the lower band, suggesting support near ₹1,057.
📈 Momentum Signals: Volume (4.23 lakh) is significantly higher than the 1-week average (2.61 lakh), showing strong participation. However, the negative MACD and weak RSI suggest selling pressure dominates.
💡 Entry Zone: Optimal entry around ₹1,070–1,100 (near support).
🚪 Exit Zone: Resistance seen at ₹1,222 (50 DMA) and ₹1,443 (200 DMA). Profit booking advised near these levels.
🔎 Trend Status: The stock is currently consolidating with bearish bias. A breakout above ₹1,222 would indicate recovery momentum.
Positive
- Strong ROCE (28.4%) and ROE (21.4%) reflect healthy returns.
- Debt-free balance sheet (Debt-to-equity 0.00).
- EPS of ₹30.1 supports earnings visibility.
- PEG ratio of 1.40 indicates reasonable growth relative to valuation.
Limitation
- Stock P/E (37.6) is higher than industry average (27.6), suggesting overvaluation.
- Trading below both 50 DMA and 200 DMA shows weak technical strength.
- Quarterly profit variation (-5.20%) indicates short-term earnings pressure.
Company Negative News
- Decline in FII holding (-0.45%) shows reduced foreign investor confidence.
- Quarterly profit decline despite revenue growth highlights margin pressure.
Company Positive News
- DII holding increased slightly (+0.03%), showing domestic support.
- PAT improved sequentially (₹70.2 Cr vs ₹62.9 Cr), indicating operational resilience.
Industry
- Industry P/E at 27.6 is lower than CONCORDBIO’s P/E, suggesting sector peers may be more attractively valued.
- Biopharma sector continues to benefit from global demand for specialty molecules and contract manufacturing.
Conclusion
⚖️ CONCORDBIO shows strong fundamentals (debt-free, healthy ROE/ROCE) but weak technical momentum. Short-term consolidation with bearish bias is evident. Entry near ₹1,070–1,100 offers margin of safety, while exits should be considered near ₹1,222–1,443. Long-term investors may hold for growth potential, but traders should wait for confirmation above 50 DMA before aggressive buying.
Would you like me to also prepare a peer benchmarking overlay comparing CONCORDBIO with other biopharma stocks (like Divi’s Lab, Biocon, Laurus Labs) to highlight relative strength and sector rotation opportunities?